De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.

Ann Hematol · 2025 · PMC12432020 · PMID 40824489

Europe PMC DOI

hedged sentence

0.6670

closest p · 13.3× alpha

0.6670

boldest claim

The sentences

did not reach statistical significancep = 0.667not close (p > 0.1)

This difference did not reach statistical significance ( p = 0.667).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.